دورية أكاديمية
Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
| العنوان: | Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms |
|---|---|
| المؤلفون: | Hélène FE Gleitz, Ai Yin Liao, James R Cook, Samuel F Rowlston, Gabriella MA Forte, Zelpha D'Souza, Claire O'Leary, Rebecca J Holley, Brian W Bigger |
| المصدر: | EMBO Molecular Medicine, Vol 10, Iss 7, Pp n/a-n/a (2018) |
| بيانات النشر: | Springer Nature, 2018. |
| سنة النشر: | 2018 |
| المجموعة: | LCC:Medicine (General) LCC:Genetics |
| مصطلحات موضوعية: | apolipoprotein E, blood–brain barrier, Hunter, mucopolysaccharidosis type II, stem cell gene therapy, Medicine (General), R5-920, Genetics, QH426-470 |
| الوصف: | Abstract The pediatric lysosomal storage disorder mucopolysaccharidosis type II is caused by mutations in IDS, resulting in accumulation of heparan and dermatan sulfate, causing severe neurodegeneration, skeletal disease, and cardiorespiratory disease. Most patients manifest with cognitive symptoms, which cannot be treated with enzyme replacement therapy, as native IDS does not cross the blood–brain barrier. We tested a brain‐targeted hematopoietic stem cell gene therapy approach using lentiviral IDS fused to ApoEII (IDS.ApoEII) compared to a lentivirus expressing normal IDS or a normal bone marrow transplant. In mucopolysaccharidosis II mice, all treatments corrected peripheral disease, but only IDS.ApoEII mediated complete normalization of brain pathology and behavior, providing significantly enhanced correction compared to IDS. A normal bone marrow transplant achieved no brain correction. Whilst corrected macrophages traffic to the brain, secreting IDS/IDS.ApoEII enzyme for cross‐correction, IDS.ApoEII was additionally more active in plasma and was taken up and transcytosed across brain endothelia significantly better than IDS via both heparan sulfate/ApoE‐dependent receptors and mannose‐6‐phosphate receptors. Brain‐targeted hematopoietic stem cell gene therapy provides a promising therapy for MPS II patients. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1757-4684 1757-4676 |
| Relation: | https://doaj.org/toc/1757-4676; https://doaj.org/toc/1757-4684 |
| DOI: | 10.15252/emmm.201708730 |
| URL الوصول: | https://doaj.org/article/7b790fd6101949a990e17c2cd9b2efa6 |
| رقم الأكسشن: | edsdoj.7b790fd6101949a990e17c2cd9b2efa6 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 17574684 17574676 |
|---|---|
| DOI: | 10.15252/emmm.201708730 |